Related Experiment Video
Updated: Jan 11, 2026
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
Association of Spondyloarthritis With Chronic Opioid Use in Inflammatory Bowel Disease: A Nationwide Danish Cohort
Rahul S Dalal1,2, Kevin Erichsen Zeiss2,3, Jan Nielsen2,3
1Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, United States.
Importance And Objective:
Chronic opioid use may increase the risk of complications in patients with inflammatory bowel disease (IBD). Rheumatologic illness has been identified as a risk factor for chronic opioid use in IBD, but the specific influence of spondyloarthritis (SpA) on this risk is unclear.
Design, Setting, And Participants:
This nationwide cohort study included adults diagnosed with Crohn's disease (CD) or ulcerative colitis (UC) between 1999 and 2021 in Denmark.
Exposures:
We compared IBD patients with SpA diagnosed within 3 years before or after the IBD diagnosis (ie IBD+SpA) and IBD patients without SpA.
Main Outcomes And Measures:
The primary outcome was chronic opioid use ≤3 years after IBD diagnosis, defined as ≥3 opioid prescriptions ≥1 month apart within a 12-month period. Using multivariable logistic regression, we determined the association of SpA with chronic opioid use while adjusting for age, sex, IBD type, year of IBD diagnosis, Charlson comorbidity index, and psychotropic medications.
Results:
We identified 45 172 patients diagnosed with IBD between 1999 and 2021, among which 666 had IBD+SpA. Chronic opioid use occurred in 20.4% of IBD+SpA versus 9.8% of IBD-only patients. SpA was associated with increased odds of chronic opioid use (adjusted odds ratio 2.78, 95% confidence interval, 2.26-3.42). Similar associations were seen across IBD+axial or peripheral SpA, UC+SpA, and CD+SpA subgroups as well as a sub-analysis of chronic use of only strong opioids.
Conclusions And Relevance:
In this nationwide cohort, SpA was strongly associated with chronic opioid use in patients diagnosed with IBD. These findings highlight IBD+SpA as a high-risk phenotype warranting early identification and multidisciplinary pain management.
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF